By Dave Sebastian

Danaher Corp. said it expects adjusted full-year core revenue growth including Cytiva to be about 20%, up from its prior guidance of a growth in the high-teens percentage.

For the third quarter, the Washington, D.C.-based science and technology conglomerat Thursday said it expects adjusted core-revenue growth to be in the mid- to high-teens percentage range.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

July 22, 2021 06:30 ET (10:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Danaher (NYSE:DHR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Danaher Charts.
Danaher (NYSE:DHR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Danaher Charts.